{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:36Z","timestamp":1786988076176,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007479","name":"Foundation of the Savings Bank of Padua and Rovigo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejmech.2026.118721","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:13:47Z","timestamp":1771978427000},"page":"118721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of a tetrahydrobenzothiophen-2-yl-pyrazolo[1,5-a]pyrimidine-3-carboxamide-based PROTAC as degrader of SARS-CoV-2 main protease"],"prefix":"10.1016","volume":"309","author":[{"given":"Michela","family":"Eleuteri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bazzacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Mercorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Desantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Zago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Cruciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Loregian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-9013","authenticated-orcid":false,"given":"Laura","family":"Goracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118721_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118721_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118721_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117212","article-title":"Recent advances in developing targeted protein degraders","volume":"284","author":"Cheng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117370","article-title":"An updated review on the role of small molecules in mediating protein degradation","volume":"287","author":"Wu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: a new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118721_bib6","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118721_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110446","article-title":"The mechanism of action and clinical value of PROTACs: a graphical review","volume":"99","author":"Graham","year":"2022","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2026.118721_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118721_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.ejmech.2026.118721_bib11","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","article-title":"NDA submission of vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4155\/fmc-2022-0005","article-title":"Proteolysis targeting chimeras in antiviral research","volume":"14","author":"Desantis","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2023.100092","article-title":"Antiviral PROTACs: opportunity borne with challenge","volume":"2","author":"Liang","year":"2023","journal-title":"Cell Insight"},{"key":"10.1016\/j.ejmech.2026.118721_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28981","article-title":"Revolutionizing viral disease treatment: PROTACs therapy could be the ultimate weapon of the future","volume":"95","author":"Mukerjee","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejmech.2026.118721_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41580-024-00761-9","article-title":"Virus-host warfare by PROTACs","volume":"25","author":"Walters","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118721_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1021\/acsbiomedchemau.2c00063","article-title":"Targeted protein degradation for infectious diseases: from basic biology to drug discovery","volume":"3","author":"Espinoza-Chavez","year":"2023","journal-title":"ACS Bio. Med. Chem. Au."},{"key":"10.1016\/j.ejmech.2026.118721_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108437","article-title":"Recent advances in PROTAC-based antiviral and antibacterial therapeutics","volume":"160","author":"Zhou","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib18","article-title":"Antiviral strategies based on targeted protein degradation: an overview of the literature and future outlook","volume":"301","author":"Zhou","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib19","doi-asserted-by":"crossref","first-page":"fuaf046","DOI":"10.1093\/femsre\/fuaf046","article-title":"PROteolysis TArgeting Chimeras (PROTACs) and beyond: targeted degradation as a new path to fight microbial pathogens","volume":"49","author":"Bazzacco","year":"2025","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2026.118721_bib20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbrc.2014.10.006","article-title":"Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus","volume":"453","author":"Montrose","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.118721_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129680","article-title":"\"PROTAC\" modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro","volume":"102","author":"Li","year":"2024","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118721_bib22","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"de Wispelaere","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118721_bib23","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41467-025-56317-8","article-title":"Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV","volume":"16","author":"Newton","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118721_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312858","article-title":"Development of a PROTAC-based targeting strategy provides a mechanistically unique mode of anti-cytomegalovirus activity","volume":"22","author":"Hahn","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118721_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2022.100030","article-title":"Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus","volume":"1","author":"Xu","year":"2022","journal-title":"Cell Insight"},{"key":"10.1016\/j.ejmech.2026.118721_bib26","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1021\/acs.jmedchem.1c02013","article-title":"Discovery of pentacyclic triterpenoid PROTACs as a class of effective hemagglutinin protein degraders","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib27","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41467-022-29690-x","article-title":"An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118721_bib28","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1038\/s41467-024-49161-9","article-title":"Broad-spectrum activity against mosquito-borne flaviviruses achieved by a targeted protein degradation mechanism","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118721_bib29","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.chembiol.2024.02.004","article-title":"PROTAC-mediated degradation of HIV-1 Nef efficiently restores cell-surface CD4 and MHC-I expression and blocks HIV-1 replication","volume":"31","author":"Emert-Sedlak","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118721_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129880","article-title":"Discovery of L15 as a novel Vif PROTAC degrader with antiviral activity against HIV-1","volume":"111","author":"Luo","year":"2024","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118721_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113814","article-title":"Indomethacin-based PROTACs as pan-coronavirus antiviral agents","volume":"226","author":"Desantis","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116202","article-title":"Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity","volume":"268","author":"Desantis","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib33","doi-asserted-by":"crossref","first-page":"27248","DOI":"10.1021\/jacs.3c12678","article-title":"A chemical strategy for the degradation of the main protease of SARS-CoV-2 in cells","volume":"145","author":"Sang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118721_bib34","article-title":"Development of de-novo coronavirus 3-chymotrypsin-like protease (3CL(pro)) inhibitors since COVID-19 outbreak: a strategy to tackle challenges of persistent virus infection","volume":"264","author":"Tian","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1021\/acsmedchemlett.3c00498","article-title":"Development of a GC-376 based peptidomimetic PROTAC as a degrader of 3-Chymotrypsin-like protease of SARS-CoV-2","volume":"15","author":"Grifagni","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118721_bib36","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1021\/acs.jmedchem.3c02416","article-title":"Discovery of first-in-class PROTAC degraders of SARS-CoV-2 main protease","volume":"67","author":"Alugubelli","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116629","article-title":"Development of novel antivrial agents that induce the degradation of the main protease of human-infecting coronaviruses","volume":"275","author":"Cheng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib38","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3390\/microorganisms13071557","article-title":"PROTAC-based antivirals for respiratory viruses: a novel approach for targeted therapy and vaccine development","volume":"13","author":"Anugu","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejmech.2026.118721_bib39","doi-asserted-by":"crossref","first-page":"7055","DOI":"10.1038\/s41598-023-34305-6","article-title":"Structural analysis of the coronavirus main protease for the design of pan-variant inhibitors","volume":"13","author":"Rungruangmaitree","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118721_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2023.102667","article-title":"Structural biology of SARS-CoV-2 M(pro) and drug discovery","volume":"82","author":"Duan","year":"2023","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejmech.2026.118721_bib41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s43856-025-00863-1","article-title":"Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus","volume":"5","author":"Pan","year":"2025","journal-title":"Commun. Med."},{"key":"10.1016\/j.ejmech.2026.118721_bib42","series-title":"Protacs Useful Against the Main Protease SARS-CoV-2. WO2024074848 A1","author":"Maple","year":"2024"},{"key":"10.1016\/j.ejmech.2026.118721_bib43","series-title":"Synthesis of PROTACs Targeting Coronavirus 3cl Protease Treating SARS-CoV-2. US11530195 B1","author":"Liang","year":"2022"},{"key":"10.1016\/j.ejmech.2026.118721_bib44","series-title":"PROTACS Targeting Viral Enzymes for Precise Treatment of COVID-19. WO2024086132 A1","author":"Han","year":"2024"},{"key":"10.1016\/j.ejmech.2026.118721_bib45","series-title":"Coronavirus Protease Degraders and Uses Thereof. WO2021231778 A1","author":"Yates","year":"2021"},{"key":"10.1016\/j.ejmech.2026.118721_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105350","article-title":"Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M(pro) by virtual screenings and hit optimization","volume":"204","author":"Mercorelli","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.118721_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.145162","article-title":"Novel SARS-CoV-2 allosteric inhibitors that destabilize the main protease M(pro) dimer","volume":"319","author":"Mercorelli","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2026.118721_bib48","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1021\/jm500300r","article-title":"Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds","volume":"57","author":"Lepri","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/ci600253e","article-title":"A common reference framework for analyzing\/comparing proteins and ligands. Fingerprints for ligands and proteins (FLAP): theory and application","volume":"47","author":"Baroni","year":"2007","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118721_bib50","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1021\/ci100221g","article-title":"FLAP: GRID molecular interaction fields in virtual screening. validation using the DUD data set","volume":"50","author":"Cross","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118721_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202400656","article-title":"Drug discovery approaches to target E3 ligases","volume":"26","author":"Rodriguez-Gimeno","year":"2025","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2026.118721_bib52","doi-asserted-by":"crossref","first-page":"21968","DOI":"10.1039\/D2RA03761K","article-title":"PROTACs bearing piperazine-containing linkers: what effect on their protonation state?","volume":"12","author":"Desantis","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.118721_bib53","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1039\/D4OB00304G","article-title":"Use of ionic liquids in amidation reactions for proteolysis targeting chimera synthesis","volume":"22","author":"Eleuteri","year":"2024","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib54","series-title":"Preparation of bi-functional Compounds Andmethods for Targeted Ubiquitination of Androgen Receptor and Androgen Receptor Splice variant-7. WO2023039604","author":"Desantis","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118721_bib55","unstructured":"Molecular discovery ltd., UK., https:\/\/www.moldiscovery.com\/software\/moka\/, (accessed December 2025)."},{"key":"10.1016\/j.ejmech.2026.118721_bib56","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/cbdv.200900153","article-title":"In silico pKa prediction and ADME profiling","volume":"6","author":"Cruciani","year":"2009","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2026.118721_bib57","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1016\/j.ejmech.2010.06.026","article-title":"Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series","volume":"45","author":"Milletti","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106247","article-title":"The protease inhibitor nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication","volume":"241","author":"Al Krad","year":"2025","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.118721_bib59","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/2472555220979584","article-title":"Target validation using PROTACs: applying the four pillars framework","volume":"26","author":"Nowak","year":"2021","journal-title":"SLAS Discov."},{"key":"10.1016\/j.ejmech.2026.118721_bib60","doi-asserted-by":"crossref","first-page":"11218","DOI":"10.1021\/acs.jmedchem.9b01393","article-title":"Discovery of highly potent and efficient PROTAC degraders of androgen receptor (AR) by employing weak binding affinity VHL E3 ligase ligands","volume":"62","author":"Han","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib61","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1021\/jacs.5c14840","article-title":"Allosteric PROTACs: expanding the horizon of targeted protein degradation","volume":"148","author":"Frost","year":"2026","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118721_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202516809","article-title":"Targeting the spliceosomal protein USP39 through allosteric ligands and PROTAC-induced degradation","volume":"65","author":"Schafer","year":"2026","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.118721_bib63","doi-asserted-by":"crossref","first-page":"16355","DOI":"10.1021\/acs.jmedchem.4c01235","article-title":"Between theory and practice: computational\/experimental integrated approaches to understand the solubility and lipophilicity of PROTACs","volume":"67","author":"Venturi","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib64","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4155\/fmc-2021-0223","article-title":"Challenges and opportunities for in vivo PROTAC delivery","volume":"14","author":"Benowitz","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib65","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118721_bib66","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejpb.2021.04.005","article-title":"Fasted and fed state human duodenal fluids: characterization, drug solubility, and comparison to simulated fluids and with human bioavailability","volume":"163","author":"Dahlgren","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejmech.2026.118721_bib67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpb.2015.02.016","article-title":"Investigation of solubilising effects of bile salts on an active pharmaceutical ingredient with unusual pH dependent solubility by NMR spectroscopy","volume":"92","author":"Vogtherr","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejmech.2026.118721_bib68","series-title":"Bi-functional Compounds and Methods for Targeted Ubiquitination of Androgen Receptor. US 20200282068","author":"Desantis","year":"2020"},{"key":"10.1016\/j.ejmech.2026.118721_bib69","doi-asserted-by":"crossref","first-page":"11615","DOI":"10.1021\/acs.jmedchem.0c00793","article-title":"Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications","volume":"63","author":"Goracci","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib70","doi-asserted-by":"crossref","first-page":"15269","DOI":"10.1021\/acs.jmedchem.3c01348","article-title":"Discovery of PVD-06 as a subtype-selective and efficient PTPN2 degrader","volume":"66","author":"Hu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib71","article-title":"Design, synthesis, and biological evaluation of trisubstituted piperazine derivatives as noncovalent severe acute respiratory syndrome coronavirus 2 main protease inhibitors with improved antiviral activity and favorable druggability","volume":"29","author":"Gao","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118721_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113494","article-title":"Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors","volume":"221","author":"Pismataro","year":"2021","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:16:15Z","timestamp":1784668575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426001662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":71,"alternative-id":["S0223523426001662"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118721","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a tetrahydrobenzothiophen-2-yl-pyrazolo[1,5-a]pyrimidine-3-carboxamide-based PROTAC as degrader of SARS-CoV-2 main protease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118721"}}